386 related articles for article (PubMed ID: 31621891)
1. Enriching cancer pharmacology with drugs of marine origin.
Jimenez PC; Wilke DV; Branco PC; Bauermeister A; Rezende-Teixeira P; Gaudêncio SP; Costa-Lotufo LV
Br J Pharmacol; 2020 Jan; 177(1):3-27. PubMed ID: 31621891
[TBL] [Abstract][Full Text] [Related]
2. Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets.
Pereira RB; Evdokimov NM; Lefranc F; Valentão P; Kornienko A; Pereira DM; Andrade PB; Gomes NGM
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31159480
[TBL] [Abstract][Full Text] [Related]
3. Marine drugs for cancer: surfacing biotechnological innovations from the oceans.
Jimenez PC; Wilke DV; Costa-Lotufo LV
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e482s. PubMed ID: 30133563
[TBL] [Abstract][Full Text] [Related]
4. Drug development from marine natural products.
Molinski TF; Dalisay DS; Lievens SL; Saludes JP
Nat Rev Drug Discov; 2009 Jan; 8(1):69-85. PubMed ID: 19096380
[TBL] [Abstract][Full Text] [Related]
5. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Barreca M; Spanò V; Montalbano A; Cueto M; Díaz Marrero AR; Deniz I; Erdoğan A; Lukić Bilela L; Moulin C; Taffin-de-Givenchy E; Spriano F; Perale G; Mehiri M; Rotter A; P Thomas O; Barraja P; Gaudêncio SP; Bertoni F
Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33291602
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug discovery from the marine environment.
Nastrucci C; Cesario A; Russo P
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):218-32. PubMed ID: 22216781
[TBL] [Abstract][Full Text] [Related]
7. Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.
Wu L; Ye K; Jiang S; Zhou G
Mar Drugs; 2021 Aug; 19(9):. PubMed ID: 34564150
[TBL] [Abstract][Full Text] [Related]
8. Development of Marine-Derived Compounds for Cancer Therapy.
Zuo W; Kwok HF
Mar Drugs; 2021 Jun; 19(6):. PubMed ID: 34203870
[TBL] [Abstract][Full Text] [Related]
9. Natural products for cancer chemotherapy.
Demain AL; Vaishnav P
Microb Biotechnol; 2011 Nov; 4(6):687-99. PubMed ID: 21375717
[TBL] [Abstract][Full Text] [Related]
10. Drugs from the deep: marine natural products as drug candidates.
Haefner B
Drug Discov Today; 2003 Jun; 8(12):536-44. PubMed ID: 12821301
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
12. The odyssey of marine pharmaceuticals: a current pipeline perspective.
Mayer AM; Glaser KB; Cuevas C; Jacobs RS; Kem W; Little RD; McIntosh JM; Newman DJ; Potts BC; Shuster DE
Trends Pharmacol Sci; 2010 Jun; 31(6):255-65. PubMed ID: 20363514
[TBL] [Abstract][Full Text] [Related]
13. Antitumoral compounds from vertebrate sister group: A review of Mediterranean ascidians.
Mauro M; Lazzara V; Punginelli D; Arizza V; Vazzana M
Dev Comp Immunol; 2020 Jul; 108():103669. PubMed ID: 32192994
[TBL] [Abstract][Full Text] [Related]
14. Complex synthesis yields breast-cancer therapy.
Ledford H
Nature; 2010 Dec; 468(7324):608-9. PubMed ID: 21124423
[No Abstract] [Full Text] [Related]
15. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
[TBL] [Abstract][Full Text] [Related]
17. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Franceschini R; Tancredi R; Pedrazzoli P; Santoro A; Zambelli A
Front Pharmacol; 2022; 13():909566. PubMed ID: 36160422
[TBL] [Abstract][Full Text] [Related]
18. Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.
Newman DJ; Cragg GM
Mar Drugs; 2014 Jan; 12(1):255-78. PubMed ID: 24424355
[TBL] [Abstract][Full Text] [Related]
19. [Clinical benefit of eribulin (Halaven
Koyama N; Taniguchi S; Kodama K; Tohyama O; Hasegawa H; Semba T
Nihon Yakurigaku Zasshi; 2016; 148(6):329-333. PubMed ID: 27904013
[No Abstract] [Full Text] [Related]
20. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
